最近,上海企业复宏汉霖研发的斯鲁利单抗注射液获得欧盟委员会批准,用于广泛期小细胞肺癌成人患者的一线治疗,成为目前唯一一个在欧盟用于广泛期小细胞肺癌治疗的抗PD-1单抗。在我国,这个创新药已获批用于治疗鳞状非小细胞肺癌、广泛期小细胞肺癌、食管鳞状细胞癌和非鳞状非小细胞肺癌。PD-1疗法起源于上世纪90年代,诺贝尔生理学或医学奖得主本庶佑发现了T细胞抑制受体PD-1,它与肿瘤细胞产生的PD-L1蛋白质...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.